Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

Wall Street had a slew of upgrades and downgrades from analysts. Here are some of the major calls for the week: J.P. Morgan ...

PTC Therapeutics faces pivotal FDA decisions for approvals that could potentially transform their long-term revenues. Click ...

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

Brown University took out another private loan, securing a $500 million agreement after the Ivy League school warned of “deep financial challenges.” The five-year loan with an unidentified lender ...

Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...

With a strong launch underway for a bladder cancer gene therapy, Ferring Pharmaceuticals is finding the kind of commercial ...

Stocks finished higher Wednesday after sliding briefly this morning following reports that President Donald Trump was giving serious thought to dismissing Federal Reserve Chair Jerome Powell.

The moves come after the S&P 500 and the Nasdaq Composite hit new all-time and closing highs during Monday’s trading session.

The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients died, the drug’s manufacturer halted dosing under pressure from the FDA.

The abrupt exit of the former CBER director raises questions about the FDA’s leadership. For now, newly appointed CDER head George Tidmarsh will take over Prasad’s post.